Friday, April 18, 2008

Novel Oral Drug, FTY720, Reduces Multiple Sclerosis Attacks
Associated Content - Denver,CO,USA
The new drug, named FTY720, is somehow revolutionary since it can be taken orally and not injected as all drug treatments for MS are currently administered. ...
See all stories on this topic

Oral Drug Shows Promise To Multiple Sclerosis Sufferers
eMaxHealth.com - Hickory,NC,USA
A new oral drug - fingolimod (FTY720) - effectively reduced relapse rates of multiple sclerosis patients in a clinical trial. The trial was conducted by ...
See all stories on this topic

Oral Multiple Sclerosis Drug Fingolimod Retains Effectiveness Over ...
DG News - USA
By Ed Susman CHICAGO -- April 17, 2008 -- More than two thirds of patients with multiple sclerosis (MS) taking the experimental oral drug fingolimod ...
See all stories on this topic


Bayhill Therapeutics Presents Data From a Phase II Trial of BHT ...
Ad-Hoc-News (Pressemitteilung) - Germany
Bayhill Therapeutics, Inc. today announced that the Company's co-founder and Vice President of Research, Hideki Garren, MD, Ph.D., gave a podium ...
See all stories on this topic


Roche Continues Solid Sales Growth in First Quarter of 2008 - Both ...
PharmaLive.com (press release) - Newtown,PA,USA
Ocrelizumab is a humanised anti-CD20 monoclonal antibody being developed by Roche, Genentech and Chugai for the treatment of autoimmune diseases. ...
See all stories on this topic


Patients denied vital MS drug
Wakefield Express - Wakefield,England,UK
Mid Yorkshire Hospitals NHS Trust has delayed providing eligible patients with Tysabri, a drug to treat relapsing remitting forms of the neurological ...
See all stories on this topic

Biogen Rejects Board Slate Put Forth by Investor Icahn
Wall Street Journal - USA
Biogen Chief Executive James Mullen contends the failure to attract bidders is because the potential risk of the multiple-sclerosis treatment Tysabri was ...
See all stories on this topic

Elan Corporation PLC (NYSE:ELN) – Company news alert regarding ...
Research Oracle (subscription) - London,England,UK
Elan Corporation PLC’s (Elan) stock price was up 11% in a single trading day due to encouraging data on global reach, safety and acceptability of TYSABRI ...
See all stories on this topic

Data Presented at the 60th Annual Meeting of the American Academy ...
PharmaLive.com (press release) - Newtown,PA,USA
The data are encouraging as they show that removal of TYSABRI through plasma exchange may be a potential intervention to rapidly clear TYSABRI and restore ...
See all stories on this topic


New Data Show Treatment Of Multiple Sclerosis (MS) With AVONEX® (interferon Beta-1a) Enhances Quality Of Life
Medical News Today Thu, 17 Apr 2008 2:17 AM PDT
Results from a one-year prospective, observational study conducted to determine the impact of beginning treatment with AVONEX on MS patients' overall quality of life (QoL) were announced today. The data showed that patients receiving treatment with AVONEX experienced statistically significant improvements in QoL, as measured by the EuroQol questionnaire (EQ-5D), compared to baseline.

Your Health: iBOT
WTVQ Lexington Thu, 17 Apr 2008 11:29 AM PDT
The iBOT gives new independence to people who rely on wheelchairs to get around. Dean Waggoner has multiple sclerosis and wants to do more than his power wheelchair will allow. So the retired construction worker decided to take the iBOT out for a test drive. "If I could have had one of these which allows you to go over 5" curbs and climb up and down steps and doesn't get stuck in sand ...

Nutra Pharma acquires remaining equity in ReceptoPharm
PharmaBiz Wed, 16 Apr 2008 10:39 PM PDT
Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, said it has acquired the remaining outstanding equity in its drug discovery holding, ReceptoPharm, Inc.

New European Multiple Sclerosis Platform Project: Roundtable For National Endorsement Of The EMSP "Code" And Consensus ...
Medical News Today Fri, 18 Apr 2008 2:13 PM PDT
Since 2003 - year of the EP resolution - EMSP (European Multiple Scleroris Platform) has been pursuing an important advocacy work focused on health inequalities in the European Union and beyond. The launch of the "Code of Good Practice" in 2007 has been a major milestone in the bid to raise awareness of Multiple Sclerosis and its impact on people's lives.

Xanthus' Symadex Reverses Disease In Preclinical Mouse Models Of Multiple Sclerosis
Medical News Today Fri, 18 Apr 2008 3:14 AM PDT
Xanthus Pharmaceuticals, Inc. presented data demonstrating that SymadexTM, a selective FLT3 inhibitor, acted to reverse disease in mouse models of both acute and chronic multiple sclerosis. Biomarkers of macrophage and dendritic cells showed a significant correction back towards the baseline levels found in healthy control animals. The results were presented in a poster session by Stephen J.

Early Treatment With COPAXONE(R) Significantly Delayed Progression To Clinically Definite Multiple Sclerosis
Medical News Today Fri, 18 Apr 2008 3:14 AM PDT
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced new results from the PreCISe study, which demonstrated that early treatment with COPAXONE® (glatiramer acetate injection) significantly reduced the risk of developing clinically definite multiple sclerosis (CDMS) by 45 percent compared to placebo (hazard ratio 0.55, p=0.0001).


Which disease to cure?
Minnesota Public Radio Fri, 18 Apr 2008 5:21 AM PDT
It's being called the Sanford Project. A year ago a Sioux Falls philanthropist gave Sanford Health $400-million. Sanford will choose to cure one of the following: lupus, childhood Diabetes, diseases caused by the human papillomavirus or pediatric Multiple Sclerosis.

Disappointing Trials Results For Sativex, UK
Medical News Today Fri, 18 Apr 2008 6:16 AM PDT
GW Pharmaceuticals, which makes Sativex - an oral spray containing a cannabis extract - has released disappointing results of a trial testing the drug's benefits in treating pain in people with multiple sclerosis (MS). The study involved 339 people experiencing neuropathic pain due to MS who have achieved inadequate pain relief with existing therapies.


Stem cell research scientific, not moral
The Daily Toreador (subscription) - Lubbock,TX,USA
... like Alzheimer's and multiple sclerosis. Stem cell research may make the long waits for organ transplants a thing of the past. Stem cells are relatively ...
See all stories on this topic

Mature B Cells Reprogrammed To Stem-cell-like State
Science Daily (press release) - USA
... new mouse models for autoimmune diseases such as multiple sclerosis and type 1 diabetes, in which the body attacks certain types of its own cells. ...
See all stories on this topic

Mature Mouse Cells Reprogrammed to Stem Cell-Like State
U.S. News & World Report - Washington,DC,USA
... cells, may help enable the creation of models that will lead to a better study and understanding of autoimmune diseases such as multiple sclerosis and ...
See all stories on this topic

1 Comments:

Blogger hima said...

The best feature of this blog is its simplicity – This is very good, I appreciate blog master for this great piece of work.. Rheumatoid Arthritis is difficult illness. But here in this blog we find excellent information about them. I hope I can link this blog from my blogs on Rheumatoid Arthritis
Rheumatoid Arthritis is a difficult illness and every one says cure is impossible. Since Rheumatoid Arthritis and its treatment is an important issue or information we need more specific information on this subject. I have found a nice informative guide on Rheumatoid Arthritis from following URL
http://www.helpcure.com/ra
Know all about Rheumatoid Arthritis here only useful and guide is here,
Hope for the best

2:12 AM  

Post a Comment

Links to this post:

Create a Link

<< Home